A decade of leadless pacemaker implantation: technical performance, safety and device longevity
Europace · 25.06.2026 · 28 (Supplement_1)
DOI: 10.1093/europace/euag105.751 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europace, online erschienen am 25.06.2026. Verfasst von J Certo Pereira und 13 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Leadless pacemakers (L-PM) eliminate the need for transvenous leads and pacemaker pockets, reducing lead-related complications. After more than a decade of clinical use worldwide, real-world data on long-term performance and management of end-of-life devices remain limited. We report a 10-year single-center experience focusing on procedural practice evolution, long-term pacing parameters, safety and battery longevity.
Methods
Single-center prospective registry including all consecutive patients undergoing L-PM implantation from May 2015 to November 2025. Clinical characteristics, procedural data, pacing parameters and estimated battery longevity were collected at implant and at latest follow-up.
Results
The cohort included 447 patients (mean age 78±10 years; 66% male). Successful implantation occurred in 445 patients (99.6%). Main pacing indications were high-grade AV block (64%), atrial fibrillation with pauses (23%), and sinus node disease (7%). Notably, 8% of implants were performed after extraction of an infected conventional system and 17% following transcatheter structural heart procedures. Procedural efficiency improved over the years, with current mean procedure and fluoroscopy times of 41.1±24.7 min and 4.4±3.8 min. Acute major complications were infrequent: pericardial effusion occurred in 1.2% (one tamponade), and 0.4% required conversion to a transvenous pacemaker (one due to acute L-PM dysfunction and the other due to a small RV cavity). Additionally, two lymphatic access-site complications were reported, one requiring surgical treatment. No device dislodgment occurred. During a mean follow-up of 2.5 ± 2.3 years, pacing parameters remained stable (threshold: 0.64 to 0.60 mV; R-wave amplitude: 12.3 to 12.5mV). Mean ventricular pacing was 59±39%. Estimated battery longevity was >8 years in 84%. Among those with >5-year follow-up (N=60; mean 6.7±2.4 years), 80% maintained >5 years of predicted longevity. Three upgrades to CRT or LBBAP occurred due to pacing-induced LV dysfunction. One true end-of-life event occurred 6 years post-implant (100% VP, low thresholds), successfully managed with a second L-PM. There were 119 deaths (27%), none device-related.
Conclusion
Over 10 years of experience, L-PM implantation proved to be a robust and safe pacing modality in routine practice, maintaining stable electrical performance and excellent battery durability, with only one device reaching end-of-life. Ongoing follow-up will clarify long-term replacement strategies and lifetime device management in this growing population.
Zitieren
APA
Pereira, J. C., Domingues, M., Costa, F. M., Gomes, D. A., Fartousse, S., Rodrigues, G., Matos, D., Carmo, J., Santos, I., Santos, P. G., Carmo, P., Morgado, F. B., Cavaco, D., & Adragao, P. (2026). A decade of leadless pacemaker implantation: technical performance, safety and device longevity. Europace, 28(Supplement_1). https://doi.org/10.1093/europace/euag105.751
Vancouver
Pereira JC, Domingues M, Costa FM, Gomes DA, Fartousse S, Rodrigues G, et al. A decade of leadless pacemaker implantation: technical performance, safety and device longevity. Europace. 2026;28(Supplement_1). doi:10.1093/europace/euag105.751
BibTeX
@article{Pereira2026,
author = {Pereira, J Certo and Domingues, M and Costa, F Moscoso and Gomes, D A and Fartousse, S and Rodrigues, G and Matos, D and Carmo, J and Santos, I and Santos, P Galvao and Carmo, P and Morgado, F Belo and Cavaco, D and Adragao, P},
title = {A decade of leadless pacemaker implantation: technical performance, safety and device longevity},
journal = {Europace},
year = {2026},
volume = {28},
number = {Supplement_1},
doi = {10.1093/europace/euag105.751}
}
EUVIMED